{"transactions":[{"id":1708019,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2023-12-18T22:09:21.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":false,"shares":2100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment with the Company through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment with the Company through such vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2100},"source":{"system":"sec-edgar","filing":"0001209191-23-058988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123058988/doc4.xml","form_type":"4"}},{"id":1708018,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-12-18T22:09:21.000Z","date":"2023-12-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":700,"price":5.69,"value":3983.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs."}],"balance_after":13233,"source":{"system":"sec-edgar","filing":"0001209191-23-058988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123058988/doc4.xml","form_type":"4"}},{"id":1708017,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-12-18T22:09:21.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":true,"shares":2100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax common stock."}],"balance_after":13933,"source":{"system":"sec-edgar","filing":"0001209191-23-058988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123058988/doc4.xml","form_type":"4"}},{"id":1843717,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2023-06-27T20:31:12.000Z","date":"2023-06-25","kind":"exercise","planned":false,"acquired":false,"shares":833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 25, 2020 grant date, in each case subject to continued employment with the Company through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 25, 2020 grant date, in each case subject to continued employment with the Company through such vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":833},"source":{"system":"sec-edgar","filing":"0001209191-23-039890","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123039890/doc4.xml","form_type":"4"}},{"id":1843716,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-27T20:31:12.000Z","date":"2023-06-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":278,"price":6.7,"value":1862.6,"ownership":{"direct":true},"balance_after":11833,"source":{"system":"sec-edgar","filing":"0001209191-23-039890","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123039890/doc4.xml","form_type":"4"}},{"id":1843715,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-27T20:31:12.000Z","date":"2023-06-25","kind":"exercise","planned":false,"acquired":true,"shares":833,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."}],"balance_after":12111,"source":{"system":"sec-edgar","filing":"0001209191-23-039890","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123039890/doc4.xml","form_type":"4"}},{"id":1955182,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-14T21:18:16.000Z","date":"2023-03-10","kind":"exercise","acquired":false,"shares":4609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date."}],"balance_after":9216,"derivative":{"underlying":"Common Stock","underlying_shares":4609},"source":{"system":"sec-edgar","filing":"0001209191-23-018547","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123018547/doc4.xml","form_type":"4"}},{"id":1955181,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-03-14T21:18:16.000Z","date":"2023-03-10","kind":"tax_withholding","acquired":false,"shares":1780,"price":6.52,"value":11605.6,"ownership":{"direct":true},"balance_after":11278,"source":{"system":"sec-edgar","filing":"0001209191-23-018547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123018547/doc4.xml","form_type":"4"}},{"id":1955180,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-03-14T21:18:16.000Z","date":"2023-03-10","kind":"exercise","acquired":true,"shares":4609,"price":6.52,"value":30050.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were received by the reporting person in connection with vesting of restricted stock units (\"RSUs\")."}],"balance_after":13058,"source":{"system":"sec-edgar","filing":"0001209191-23-018547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123018547/doc4.xml","form_type":"4"}},{"id":1961627,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-09T22:00:34.000Z","date":"2023-03-07","kind":"grant","acquired":true,"shares":38330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date."}],"balance_after":38330,"derivative":{"underlying":"Common Stock","underlying_shares":38330},"source":{"system":"sec-edgar","filing":"0001209191-23-017583","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123017583/doc4.xml","form_type":"4"}},{"id":1961626,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-09T22:00:34.000Z","date":"2023-03-07","kind":"grant","acquired":true,"shares":44280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the \"Company\") Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\"), will vest on the first anniversary of the March 7, 2023 grant date (the \"Grant Date\"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date."}],"balance_after":44280,"derivative":{"exercise_price":6.97,"exercise_date":"2024-03-07","expiration_date":"2033-03-07","underlying":"Common Stock","underlying_shares":44280},"source":{"system":"sec-edgar","filing":"0001209191-23-017583","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123017583/doc4.xml","form_type":"4"}},{"id":2084258,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2022-12-16T22:02:27.000Z","date":"2022-12-14","kind":"exercise","acquired":false,"shares":2100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date."}],"balance_after":2100,"derivative":{"underlying":"Common Stock","underlying_shares":2100},"source":{"system":"sec-edgar","filing":"0001209191-22-061705","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122061705/doc4.xml","form_type":"4"}},{"id":2084257,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-12-16T22:02:27.000Z","date":"2022-12-14","kind":"tax_withholding","acquired":false,"shares":700,"price":17.23,"value":12061.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The shares reported on this Form 4 are subject to a lock-up agreement between the Reporting Person, J.P. Morgan Securities LLC and Jefferies LLC, dated December 14, 2022."}],"balance_after":8449,"source":{"system":"sec-edgar","filing":"0001209191-22-061705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122061705/doc4.xml","form_type":"4"}},{"id":2084256,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-12-16T22:02:27.000Z","date":"2022-12-14","kind":"exercise","acquired":true,"shares":2100,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were received by the Reporting Person in connection with vesting of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."}],"balance_after":9149,"source":{"system":"sec-edgar","filing":"0001209191-22-061705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122061705/doc4.xml","form_type":"4"}},{"id":2150104,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2022-09-28T21:00:57.000Z","date":"2022-09-26","kind":"exercise","acquired":false,"shares":667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued service with the Company through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued service with the Company through such vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":667},"source":{"system":"sec-edgar","filing":"0001209191-22-051471","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122051471/doc4.xml","form_type":"4"}},{"id":2150103,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2022-09-28T21:00:57.000Z","date":"2022-09-26","kind":"exercise","acquired":false,"shares":3973,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the September 26, 2019 grant date (the \"Grant Date\"), in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the September 26, 2019 grant date (the \"Grant Date\"), in each case subject to continued employment through such vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3973},"source":{"system":"sec-edgar","filing":"0001209191-22-051471","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122051471/doc4.xml","form_type":"4"}},{"id":2150102,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:00:57.000Z","date":"2022-09-26","kind":"tax_withholding","acquired":false,"shares":258,"price":18.87,"value":4868.46,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":3384,"source":{"system":"sec-edgar","filing":"0001209191-22-051471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122051471/doc4.xml","form_type":"4"}},{"id":2150101,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:00:57.000Z","date":"2022-09-26","kind":"exercise","acquired":true,"shares":667,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":3642,"source":{"system":"sec-edgar","filing":"0001209191-22-051471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122051471/doc4.xml","form_type":"4"}},{"id":2150100,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:00:57.000Z","date":"2022-09-26","kind":"tax_withholding","acquired":false,"shares":1324,"price":18.87,"value":24983.88,"ownership":{"direct":true},"balance_after":7049,"source":{"system":"sec-edgar","filing":"0001209191-22-051471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122051471/doc4.xml","form_type":"4"}},{"id":2150099,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:00:57.000Z","date":"2022-09-26","kind":"exercise","acquired":true,"shares":3973,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."}],"balance_after":8373,"source":{"system":"sec-edgar","filing":"0001209191-22-051471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122051471/doc4.xml","form_type":"4"}},{"id":2173259,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2022-08-26T22:42:40.000Z","date":"2022-08-24","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On April 17, 2020, the reporting person's spouse, who is a consultant for the Company, was granted 4,000 RSUs pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the RSUs subject to this grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the RSUs vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the RSUs vested on August 24, 2022, the second anniversary of the initiation date subject to continued service with the Company through such vesting date."}],"balance_after":0,"derivative":{"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-22-047756","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122047756/doc4.xml","form_type":"4"}},{"id":2173258,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-08-26T22:42:40.000Z","date":"2022-08-24","kind":"tax_withholding","acquired":false,"shares":772,"price":37.07,"value":28618.04,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":2975,"source":{"system":"sec-edgar","filing":"0001209191-22-047756","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122047756/doc4.xml","form_type":"4"}},{"id":2173257,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-08-26T22:42:40.000Z","date":"2022-08-24","kind":"exercise","acquired":true,"shares":2000,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":3747,"source":{"system":"sec-edgar","filing":"0001209191-22-047756","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122047756/doc4.xml","form_type":"4"}},{"id":2220478,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2022-06-28T21:05:54.000Z","date":"2022-06-25","kind":"exercise","acquired":false,"shares":833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 25, 2020 grant date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 25, 2020 grant date, in each case subject to continued employment through such vesting date."}],"balance_after":833,"derivative":{"underlying":"Common Stock","underlying_shares":833},"source":{"system":"sec-edgar","filing":"0001209191-22-039638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122039638/doc4.xml","form_type":"4"}},{"id":2220477,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-06-28T21:05:54.000Z","date":"2022-06-25","kind":"tax_withholding","acquired":false,"shares":278,"price":51.67,"value":14364.26,"ownership":{"direct":true},"balance_after":4400,"source":{"system":"sec-edgar","filing":"0001209191-22-039638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122039638/doc4.xml","form_type":"4"}},{"id":2220476,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-06-28T21:05:54.000Z","date":"2022-06-25","kind":"exercise","acquired":true,"shares":833,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."}],"balance_after":4678,"source":{"system":"sec-edgar","filing":"0001209191-22-039638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122039638/doc4.xml","form_type":"4"}},{"id":2336251,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-14T23:47:52.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":13825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date."}],"balance_after":13825,"derivative":{"underlying":"Common Stock","underlying_shares":13825},"source":{"system":"sec-edgar","filing":"0001209191-22-018658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122018658/doc4.xml","form_type":"4"}},{"id":2336250,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-14T23:47:52.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":20737,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the \"Company\") Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\"), will vest on the first anniversary of the March 10, 2022 grant date (the \"Grant Date\"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date."}],"balance_after":20737,"derivative":{"exercise_price":77.77,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":20737},"source":{"system":"sec-edgar","filing":"0001209191-22-018658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122018658/doc4.xml","form_type":"4"}},{"id":2445440,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T22:22:06.000Z","date":"2022-01-03","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"On April 17, 2020, the reporting person was granted an option to purchase 125,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":19.08,"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-22-001815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122001815/doc4.xml","form_type":"4"}},{"id":2445439,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T22:22:06.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":100,"price":144.43,"value":14443.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":3845,"source":{"system":"sec-edgar","filing":"0001209191-22-001815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122001815/doc4.xml","form_type":"4"}},{"id":2445438,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T22:22:06.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":1003,"price":143.639,"value":144069.917,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.38 to $143.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3945,"source":{"system":"sec-edgar","filing":"0001209191-22-001815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122001815/doc4.xml","form_type":"4"}},{"id":2445437,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T22:22:06.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":800,"price":142.6463,"value":114117.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.25 to $142.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4948,"source":{"system":"sec-edgar","filing":"0001209191-22-001815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122001815/doc4.xml","form_type":"4"}},{"id":2445436,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T22:22:06.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":800,"price":141.6875,"value":113350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.22 to $142.04, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5748,"source":{"system":"sec-edgar","filing":"0001209191-22-001815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122001815/doc4.xml","form_type":"4"}},{"id":2445435,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T22:22:06.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":500,"price":140.052,"value":70026.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.68 to $140.31, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6548,"source":{"system":"sec-edgar","filing":"0001209191-22-001815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122001815/doc4.xml","form_type":"4"}},{"id":2445434,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T22:22:06.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":997,"price":139.0768,"value":138659.5696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.63 to $139.41, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7048,"source":{"system":"sec-edgar","filing":"0001209191-22-001815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122001815/doc4.xml","form_type":"4"}},{"id":2445433,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T22:22:06.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":400,"price":137.85,"value":55140.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.60 to $138.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":8045,"source":{"system":"sec-edgar","filing":"0001209191-22-001815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122001815/doc4.xml","form_type":"4"}},{"id":2445432,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T22:22:06.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":400,"price":136.82,"value":54728.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.29 to $137.26, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":8445,"source":{"system":"sec-edgar","filing":"0001209191-22-001815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122001815/doc4.xml","form_type":"4"}},{"id":2445431,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T22:22:06.000Z","date":"2022-01-03","kind":"exercise","acquired":true,"shares":5000,"price":19.08,"value":95400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":8845,"source":{"system":"sec-edgar","filing":"0001209191-22-001815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122001815/doc4.xml","form_type":"4"}},{"id":2461515,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T22:03:41.000Z","date":"2021-12-20","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On April 17, 2020, the reporting person was granted an option to purchase 125,000 shares of common stock of Novavax, Inc. (the \"Company\") pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date."}],"balance_after":85000,"derivative":{"exercise_price":19.08,"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-070957","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070957/doc4.xml","form_type":"4"}},{"id":2461514,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-22T22:03:41.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":5000,"price":230,"value":1150000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":3845,"source":{"system":"sec-edgar","filing":"0001209191-21-070957","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070957/doc4.xml","form_type":"4"}},{"id":2461513,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-22T22:03:41.000Z","date":"2021-12-20","kind":"exercise","acquired":true,"shares":5000,"price":19.08,"value":95400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":8845,"source":{"system":"sec-edgar","filing":"0001209191-21-070957","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070957/doc4.xml","form_type":"4"}},{"id":2470475,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2021-12-16T22:16:50.000Z","date":"2021-12-14","kind":"exercise","acquired":false,"shares":2100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date."}],"balance_after":4200,"derivative":{"underlying":"Common Stock","underlying_shares":2100},"source":{"system":"sec-edgar","filing":"0001209191-21-070017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070017/doc4.xml","form_type":"4"}},{"id":2470474,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-16T22:16:50.000Z","date":"2021-12-14","kind":"tax_withholding","acquired":false,"shares":1015,"price":168.43,"value":170956.45,"ownership":{"direct":true},"balance_after":3845,"source":{"system":"sec-edgar","filing":"0001209191-21-070017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070017/doc4.xml","form_type":"4"}},{"id":2470473,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-16T22:16:50.000Z","date":"2021-12-14","kind":"exercise","acquired":true,"shares":2100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."}],"balance_after":4860,"source":{"system":"sec-edgar","filing":"0001209191-21-070017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121070017/doc4.xml","form_type":"4"}},{"id":2487018,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-03T23:30:01.000Z","date":"2021-12-01","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"On April 17, 2020, the reporting person was granted an option to purchase 125,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date."}],"balance_after":90000,"derivative":{"exercise_price":19.08,"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-067969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067969/doc4.xml","form_type":"4"}},{"id":2487017,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:30:01.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":366,"price":202.3617,"value":74064.3822,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.23 to $202.50, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":2760,"source":{"system":"sec-edgar","filing":"0001209191-21-067969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067969/doc4.xml","form_type":"4"}},{"id":2487016,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:30:01.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":300,"price":200.92,"value":60276.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.75 to $201.12, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3126,"source":{"system":"sec-edgar","filing":"0001209191-21-067969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067969/doc4.xml","form_type":"4"}},{"id":2487015,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:30:01.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":300,"price":199.8133,"value":59943.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.62 to $200.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3426,"source":{"system":"sec-edgar","filing":"0001209191-21-067969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067969/doc4.xml","form_type":"4"}},{"id":2487014,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:30:01.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":400,"price":198.35,"value":79340.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.90 to $198.76, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3726,"source":{"system":"sec-edgar","filing":"0001209191-21-067969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067969/doc4.xml","form_type":"4"}},{"id":2487013,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:30:01.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":300,"price":197.1867,"value":59156.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.73 to $197.51, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4126,"source":{"system":"sec-edgar","filing":"0001209191-21-067969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067969/doc4.xml","form_type":"4"}},{"id":2487012,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:30:01.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":943,"price":196.1101,"value":184931.8243,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.70 to $196.65, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4426,"source":{"system":"sec-edgar","filing":"0001209191-21-067969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067969/doc4.xml","form_type":"4"}},{"id":2487011,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:30:01.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":900,"price":194.5389,"value":175085.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.25 to $195.09, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5369,"source":{"system":"sec-edgar","filing":"0001209191-21-067969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067969/doc4.xml","form_type":"4"}},{"id":2487010,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:30:01.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":800,"price":193.7925,"value":155034.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.24 to $194.17, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6269,"source":{"system":"sec-edgar","filing":"0001209191-21-067969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067969/doc4.xml","form_type":"4"}},{"id":2487009,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:30:01.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":691,"price":192.6378,"value":133112.7198,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.24 to $192.99, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7069,"source":{"system":"sec-edgar","filing":"0001209191-21-067969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067969/doc4.xml","form_type":"4"}},{"id":2487008,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:30:01.000Z","date":"2021-12-01","kind":"exercise","acquired":true,"shares":5000,"price":19.08,"value":95400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":7760,"source":{"system":"sec-edgar","filing":"0001209191-21-067969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067969/doc4.xml","form_type":"4"}},{"id":2491108,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-01T22:02:55.000Z","date":"2021-11-29","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On April 17, 2020, the reporting person was granted an option to purchase 125,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date."}],"balance_after":95000,"derivative":{"exercise_price":19.08,"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-067292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067292/doc4.xml","form_type":"4"}},{"id":2491107,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-01T22:02:55.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":5000,"price":228.72,"value":1143600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2760,"source":{"system":"sec-edgar","filing":"0001209191-21-067292","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067292/doc4.xml","form_type":"4"}},{"id":2491106,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-01T22:02:55.000Z","date":"2021-11-29","kind":"exercise","acquired":true,"shares":5000,"price":19.08,"value":95400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":7760,"source":{"system":"sec-edgar","filing":"0001209191-21-067292","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121067292/doc4.xml","form_type":"4"}},{"id":2523637,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-05T21:02:19.000Z","date":"2021-11-03","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On April 17, 2020, the reporting person was granted an option to purchase 125,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":19.08,"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-063205","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121063205/doc4.xml","form_type":"4"}},{"id":2523636,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:02:19.000Z","date":"2021-11-03","kind":"sale","acquired":false,"shares":5000,"price":200,"value":1000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2760,"source":{"system":"sec-edgar","filing":"0001209191-21-063205","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121063205/doc4.xml","form_type":"4"}},{"id":2523635,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:02:19.000Z","date":"2021-11-03","kind":"exercise","acquired":true,"shares":5000,"price":19.08,"value":95400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":7760,"source":{"system":"sec-edgar","filing":"0001209191-21-063205","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121063205/doc4.xml","form_type":"4"}},{"id":2527268,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"On April 17, 2020, the reporting person was granted an option to purchase 125,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date."}],"balance_after":105000,"derivative":{"exercise_price":19.08,"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527267,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":157,"price":173.15,"value":27184.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2760,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527266,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":300,"price":172.4433,"value":51732.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.02 to $172.67, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":2917,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527265,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":500,"price":170.882,"value":85441.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.52 to $171.21, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3217,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527264,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":200,"price":169.045,"value":33809.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.99 to $169.10, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3717,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527263,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":400,"price":168.32,"value":67328.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.86 to $168.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3917,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527262,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":200,"price":167.145,"value":33429.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.81 to $167.48, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4317,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527261,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":200,"price":165.665,"value":33133.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.39 to $165.94, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4517,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527260,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":300,"price":164.0167,"value":49205.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.69 to $164.58, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4717,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527259,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":100,"price":162.69,"value":16269.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":5017,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527258,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":400,"price":162.1,"value":64840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.64 to $162.30, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5117,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527257,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":343,"price":159.904,"value":54847.072,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.56 to $160.40, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5517,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527256,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":400,"price":158.535,"value":63414.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.17 to $159.13, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5860,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527255,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":800,"price":157.42,"value":125936.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.04 to $157.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6260,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527254,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":300,"price":155.96,"value":46788.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.85 to $156.16, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7060,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527253,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":400,"price":155.1625,"value":62065.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.65 to $155.48, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7360,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2527252,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:49:12.000Z","date":"2021-11-01","kind":"exercise","acquired":true,"shares":5000,"price":19.08,"value":95400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":7760,"source":{"system":"sec-edgar","filing":"0001209191-21-062725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121062725/doc4.xml","form_type":"4"}},{"id":2549989,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"On April 17, 2020, the reporting person was granted an option to purchase 125,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date."}],"balance_after":110000,"derivative":{"exercise_price":19.08,"expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549988,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":48,"price":190.63,"value":9150.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2760,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549987,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":300,"price":189.6833,"value":56904.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.62 to $189.79, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":2808,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549986,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":100,"price":181.36,"value":18136.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":3108,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549985,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":352,"price":179.2695,"value":63102.864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.88 to $179.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3208,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549984,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":600,"price":177.9967,"value":106798.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.55 to $178.43, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3560,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549983,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":500,"price":177.018,"value":88509.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.53 to $177.42, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4160,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549982,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":500,"price":175.906,"value":87953.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.42 to $176.40, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":4660,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549981,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":400,"price":174.7375,"value":69895.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.35 to $175.26, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5160,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549980,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":400,"price":173.825,"value":69530.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.31 to $174.12, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5560,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549979,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":200,"price":172.46,"value":34492.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.25 to $172.67, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":5960,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549978,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":600,"price":171.6,"value":102960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.24 to $171.94, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6160,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549977,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":200,"price":169.17,"value":33834.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.78 to $169.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6760,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549976,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":300,"price":168.0333,"value":50409.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.69 to $168.39, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":6960,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549975,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":100,"price":166.19,"value":16619.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":7260,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549974,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":400,"price":165.395,"value":66158.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.00 to $165.58, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":7360,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2549973,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:02:29.000Z","date":"2021-10-01","kind":"exercise","acquired":true,"shares":5000,"price":19.08,"value":95400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":7760,"source":{"system":"sec-edgar","filing":"0001209191-21-059543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121059543/doc4.xml","form_type":"4"}},{"id":2558085,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-28T21:04:49.000Z","date":"2021-09-26","kind":"exercise","acquired":false,"shares":666,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued service with the Company through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued service with the Company through such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":667,"derivative":{"underlying":"Common Stock","underlying_shares":666},"source":{"system":"sec-edgar","filing":"0001209191-21-057940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121057940/doc4.xml","form_type":"4"}},{"id":2558084,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-28T21:04:49.000Z","date":"2021-09-26","kind":"exercise","acquired":false,"shares":3973,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the September 26, 2019 grant date (the \"Grant Date\"), in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the September 26, 2019 grant date (the \"Grant Date\"), in each case subject to continued employment through such vesting date."}],"balance_after":3973,"derivative":{"underlying":"Common Stock","underlying_shares":3973},"source":{"system":"sec-edgar","filing":"0001209191-21-057940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121057940/doc4.xml","form_type":"4"}},{"id":2558083,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-09-28T21:04:49.000Z","date":"2021-09-26","kind":"tax_withholding","acquired":false,"shares":222,"price":248.16,"value":55091.52,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1747,"source":{"system":"sec-edgar","filing":"0001209191-21-057940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121057940/doc4.xml","form_type":"4"}},{"id":2558082,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-09-28T21:04:49.000Z","date":"2021-09-26","kind":"exercise","acquired":true,"shares":666,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1969,"source":{"system":"sec-edgar","filing":"0001209191-21-057940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121057940/doc4.xml","form_type":"4"}},{"id":2558081,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":96110,"kind":"person","name":"Herrmann John A III","position":1,"cik":"0001610928","reported_name":"Herrmann John A III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-09-28T21:04:49.000Z","date":"2021-09-26","kind":"tax_withholding","acquired":false,"shares":1919,"price":248.16,"value":476219.04,"ownership":{"direct":true},"balance_after":2760,"source":{"system":"sec-edgar","filing":"0001209191-21-057940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121057940/doc4.xml","form_type":"4"}}],"next_cursor":"2021-09-28T21:04:49.000000Z,2558081"}